Journal article

Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance

Steve Pedrini, Eugene Hone, Veer B Gupta, Ian James, Elham Teimouri, Ashley Bush, Christopher C Rowe, Victor L Villemagne, David Ames, Colin L Masters, Stephanie Rainey-Smith, Giuseppe Verdile, Hamid R Sohrabi, Manfred R Raida, Markus R Wenk, Kevin Taddei, Pratishtha Chatterjee, Ian Martins, Simon M Laws, Ralph N Martins

Journal of Alzheimer's Disease | IOS PRESS | Published : 2020

Abstract

BACKGROUND: The link between cholesterol and Alzheimer's disease (AD) has received much attention, as evidence suggests high levels of cholesterol might be an AD risk factor. The carriage of cholesterol and lipids through the body is mediated via lipoproteins, some of which, particularly apolipoprotein E (ApoE), are intimately linked with AD. In humans, high density lipoprotein (HDL) is regarded as a "good" lipid complex due to its ability to enable clearance of excess cholesterol via 'cholesterol reverse transport', although its activities in the pathogenesis of AD are poorly understood. There are several subclasses of HDL; these range from the newly formed small HDL, to much larger HDL. OB..

View full abstract

Grants

Funding Acknowledgements

We thank all the participants who took part in this study and the clinicians who referred participants. The AIBL study (http://www.AIBL.csiro.au) is a collaboration between CSIRO, Edith Cowan University (ECU), The Florey Institute of Neuroscience and Mental Health (FINMH), National Ageing Research Institute (NARI) and Austin Health. The authors acknowledge the financial support of the Cooperative Research Centre for Mental Health (CRCMH), the CRCMH program is an Australian Government Initiative, McCusker Alzheimer's Research Foundation, Alzheimer's Australia Research Foundation (AARF), the Science and Industry Endowment Fund, CSIRO, Brightfocus, USA and the WA Dept. of Health. FINMH acknowledges the funding support from the Victorian Government's Operational Infrastructure Support program. Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. Authors' disclosures available online (https://www.j-alz.com/manuscript-disclosures/20-0291r1).